Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TriSalus Life Sciences (TLSI) Operating Expenses (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Operating Expenses data on record, last reported at $6.7 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 11.48% year-over-year to $6.7 million; the TTM value through Dec 2025 reached $36.4 million, up 2.16%, while the annual FY2025 figure was $36.4 million, 2.16% up from the prior year.
  • Operating Expenses reached $6.7 million in Q4 2025 per TLSI's latest filing, down from $11.8 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $18.6 million in Q3 2023 and bottomed at $288273.0 in Q2 2022.
  • Average Operating Expenses over 4 years is $9.2 million, with a median of $9.1 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: skyrocketed 3978.77% in 2023, then plummeted 51.87% in 2024.
  • A 4-year view of Operating Expenses shows it stood at $17.4 million in 2022, then decreased by 20.6% to $13.8 million in 2023, then plummeted by 44.75% to $7.6 million in 2024, then decreased by 11.48% to $6.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $6.7 million in Q4 2025, $11.8 million in Q3 2025, and $9.6 million in Q2 2025.